When was Syncromune founded?

Syncromune was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Syncromune located?

Syncromune is headquartered in Fort Lauderdale, United States.

Who is the current CEO of Syncromune?

Eamonn Hobbs of Syncromune. They have also founded 1 company.

How many employees does Syncromune have?

As of Sep 30, 2026, the latest employee count at Syncromune is 61.

Is Syncromune a funded company?

Syncromune is a funded company, having raised a total of $159M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 29, 2022.

When was the latest funding round of Syncromune?

Syncromune's latest funding was a $***** Series A round on Dec 03, 2024, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $4.09B in funding in 2026 to date.

Where does Syncromune rank among its competitors?

Syncromune ranks 1098th amongst 3476 active competitors, of which 1143 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Syncromune?

Syncromune's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Syncromune - 2026 Company Profile, Team, Funding & Competitors

Syncromune is a series A company based in Fort Lauderdale (United States), founded in 2020 by Eamonn Hobbs. It operates as a Developer of therapeutic vaccines for the treatment of cancer. Syncromune has raised $159M in funding. The company has 3476 active competitors, including 1143 funded and 805 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of therapeutic vaccines for the treatment of cancer. The company has developed Syncrovax platform by utilizing intratumoral sync technology (IST) to design cancer therapies. The product pipeline includes NSC-IST, BRC-IST, OVN-IST, PRC-IST for the treatment of lung, breast, ovarian, and breast cancers.

Website: syncromune.com
Social
Email ID: *****@syncromune.com

Key Metrics

Founded Year

2020

Location

Fort Lauderdale, United States

Stage

Series A

Total Funding

$159M in 2 rounds

Latest Funding Round

Series A, Dec 03, 2024, $*****

Ranked

1098^th among 3476 active competitors

Employee Count

61 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3120 more

View Syncromune's full profile

Syncromune has raised a total funding of $159M over 2 rounds. Its first funding round was on Nov 29, 2022.

Here is the list of recent funding rounds of Syncromune:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 03, 2024	8323257	Series A	3360054	4804148	6338393	4266069
Nov 29, 2022	5300649	Series A	5775053	6810287	8399508	5643991

Access funding benchmarks and valuations. Sign up today!

View details of Syncromune's funding rounds and investors

The founders of Syncromune is Eamonn Hobbs. Eamonn Hobbs is the CEO of Syncromune.

Here are the details of Syncromune's key team members:

Eamonn Hobbs: Founder & CEO & President of Syncromune.
Contact Info: 1 email address

View details of Syncromune's Founder profiles and Board Members

Syncromune's employee count trend

Syncromune has 61 employees as of Sep 26. Here is Syncromune's employee count trend over the years:

Uncover Syncromune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syncromune include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Syncromune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
1098th	Syncromune 2020, Fort Lauderdale (United States), Series A	Developer of therapeutic vaccines for the treatment of cancer	$159M	-	40/100